bioMérieux’s CHROMID® Strepto B still adapted to the NEW ASM Guidelines 2020

In the new Guidelines for the Detection and Identification of Group B Streptococcus, the ASM mentions the CHROMID® Strepto B as medium for GBS detection1. After an enrichment step, in 18-24 hours of incubation, CHROMID® Strepto B provides:

  • Selective and chromogenic isolation for the screening of group B streptococci (S. agalactiae)
  • Detection of hemolytic and non-hemolytic GBS
  • Excellent performance for GBS prenatal screening in terms of nutrient capacity and sensitivity of detection
  • FDA-approved medium
  • Compatible with PhenoMATRIX® and WASPLab®

 

Learn more about CHROMID® Strepto B

 

  1. https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of

Maximize CHROMID® Strepto B with WASPLab® empowered by bioMérieux

Take advantage of CHROMID® Strepto B performances combining automation and efficiency using WASPLab® onboarding PhenoMATRIX®.

PhenoMATRIX® is an advanced set of highly sophisticated AI that gives WASPLab® users the power to automatically pre-assess and pre-sort culture plates, read, interpret and segregate bacterial cultures. By grouping negative cultures, which are the majority of the cultures screened, staff can quickly review up to 40 plates per computer screen and batch release negative results — eliminating the need to review each plate manually — saving time and freeing up technicians to focus on more complex tasks.

In a recent study*, the use of CHROMID® Strepto B (after enrichment in LIM broth) in combination with WASPLab® and PhenoMATRIX® has shown a sensitivity equivalent to molecular detection, providing an efficient method for the rapid screening of GBS negative cultures.

*Digital image analysis for the detection of Group B Streptococcus from CHROMID® StreptoB Media using a PhenoMatrix® Artificial Intelligence Software Algorithm, J. Baker et al., October 2020, Journal of Clinical Microbiology 59(1)

 

Learn more about WASPlab®

 

Article synopsis: The impact of universal screening in Taiwan

We found this 2018 study, conducted after universal screening was implemented in Taiwan, to be informative and interesting. You can read our synopsis here and click on the link below to read the full article.

 

“Risk factors for neonatal early-onset group B streptococcus-related diseases after the implementation of a universal screening program in Taiwan”

Li-Chen Hung, Pei-Tseng Kung, Tsan-Hung Chiu, Hsun-Pi Su, Ming Ho, Hui-Fen Kao, Li-Ting Chiu, Kuang-Hua Huang and Wen-Chen Tsai BMC Public Health (2018) 18:438

Article synopsis provided by bioMérieux

Universal screening for Group B streptococcus (GBS) was introduced in Taiwan in 2012. Both before universal screening and in the first year, GBS prevalence in pregnant women in Taiwan was about 20%, similar to many other areas of the world. The screening program was implemented to detect GBS-carrying pregnant women early and provide intrapartum antibiotic prophylaxis, thereby protecting newborns from early-onset GBS-related diseases: neonatal sepsis, meningitis and pneumonia.

This retrospective study looked at women who gave birth naturally between April 15, 2012 and December 31, 2013. Using government data, they calculated GBS prevalence among mothers, and morbidity and mortality among newborns to evaluate the impact of universal screening.

The results after universal screening was implemented were clear:

  • The rate of early-onset infection from GBS dropped from 0.1% to 0.02%, which translates to as much as 80% decrease
  • The study authors note that this 80% decrease is similar to that observed in other regions where screening has been implemented, such as the US1
  • The factors contributing to GBS infection were reduced to only three:
    • GBS screening positive result
    • CCI (Charlson comorbidity index)
    • Preterm birth

The authors concluded:

“The implementation of the universal GBS screening program decreased the infection rate of neonatal early-onset GBS diseases. The effects of socioeconomic factors and high-risk pregnancy on early-onset GBS infections were weakened.”

 

Read the full article here

 

 

  1. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010: Department of Health and Human Services. Centers for Disease Control and Prevention. 2010;59:1–32.